Skip to main
SBRA
SBRA logo

SBRA Stock Forecast & Price Target

SBRA Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 0%
Buy 38%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Sabra Health Care REIT has demonstrated continued improvements in occupancy rates and rent coverage, contributing to an attractive valuation relative to its peers. The anticipated recovery in the seniors housing managed portfolio is expected to enhance the company's leverage profile, providing opportunities for accretive growth. Additionally, favorable demand drivers in the healthcare real estate sector, combined with Sabra's above-average RIDEA exposure, position the company to effectively capitalize on market conditions moving forward.

Bears say

Sabra Health Care REIT faces a negative outlook primarily due to the uncertainty surrounding individual operator performance, which has resulted in difficulties for some operators to fulfill rent obligations amid an inflationary environment. Furthermore, the company is considered to be more leveraged compared to several peers, and its stock is trading near the high end of its historical valuation range, indicating limited potential for earnings growth through future acquisitions. Lastly, the current cost of equity is perceived to restrict the company's ability to generate immediate earnings accretion, complicating its competitive positioning within the healthcare REIT sector.

SBRA has been analyzed by 8 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 38% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sabra Health Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sabra Health Care (SBRA) Forecast

Analysts have given SBRA a Hold based on their latest research and market trends.

According to 8 analysts, SBRA has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sabra Health Care (SBRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.